Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
replicon RNA COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- VLP Therapeutics Japan
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The replicon RNA COVID-19 vaccine is a self-amplifying RNA (saRNA) vaccine candidate being developed for the prevention of COVID-19. Unlike conventional mRNA vaccines, saRNA utilizes a replicase complex (typically derived from alphaviruses) that allows the RNA to self-amplify within the host cell after administration. This mechanism leads to sustained and high-level expression of the encoded antigen—in this case, the SARS-CoV-2 spike protein—which can potentially achieve robust immune responses at significantly lower doses than standard mRNA vaccines. The Research Institute for Microbial Diseases (BIKEN Foundation) and VLP Therapeutics Japan entered into a Memorandum of Understanding in September 2023 to collaborate on the development and manufacturing of this vaccine, which is currently in the preclinical stage.
- Other names
- replicon RNA COVID-19 vaccineself-amplifying RNA COVID-19 vaccinesaRNA COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on replicon RNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on replicon RNA COVID-19 vaccine.